Healios Kk Stock Performance
| HLOSF Stock | USD 1.93 0.38 16.45% |
The company retains a Market Volatility (i.e., Beta) of 0.51, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Healios KK's returns are expected to increase less than the market. However, during the bear market, the loss of holding Healios KK is expected to be smaller as well. At this point, Healios KK has a negative expected return of -1.08%. Please make sure to check out Healios KK's treynor ratio, and the relationship between the standard deviation and accumulation distribution , to decide if Healios KK performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Healios KK has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fragile performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in January 2026. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
| Begin Period Cash Flow | 13.9 B | |
| Total Cashflows From Investing Activities | -736 M | |
| Free Cash Flow | -5.4 B |
Healios |
Healios KK Relative Risk vs. Return Landscape
If you would invest 415.00 in Healios KK on September 26, 2025 and sell it today you would lose (222.00) from holding Healios KK or give up 53.49% of portfolio value over 90 days. Healios KK is currently producing negative expected returns and takes up 4.4621% volatility of returns over 90 trading days. Put another way, 40% of traded pink sheets are less volatile than Healios, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Healios KK Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Healios KK's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Healios KK, and traders can use it to determine the average amount a Healios KK's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2409
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | HLOSF |
Based on monthly moving average Healios KK is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Healios KK by adding Healios KK to a well-diversified portfolio.
Healios KK Fundamentals Growth
Healios Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Healios KK, and Healios KK fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Healios Pink Sheet performance.
| Return On Equity | -0.68 | |||
| Return On Asset | -0.17 | |||
| Operating Margin | (136.90) % | |||
| Current Valuation | 131.57 M | |||
| Shares Outstanding | 60.62 M | |||
| Price To Earning | 3.68 X | |||
| Price To Book | 11.65 X | |||
| Price To Sales | 21.51 X | |||
| Revenue | 41 M | |||
| EBITDA | (3.4 B) | |||
| Cash And Equivalents | 12.28 B | |||
| Cash Per Share | 237.66 X | |||
| Total Debt | 6.82 B | |||
| Debt To Equity | 1.61 % | |||
| Book Value Per Share | 77.68 X | |||
| Cash Flow From Operations | (5.09 B) | |||
| Earnings Per Share | (0.80) X | |||
| Total Asset | 23.97 B | |||
| Retained Earnings | (21.04 M) | |||
| Current Asset | 368 K | |||
| Current Liabilities | 232 K | |||
About Healios KK Performance
By analyzing Healios KK's fundamental ratios, stakeholders can gain valuable insights into Healios KK's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Healios KK has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Healios KK has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Healios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. Healios K.K. was incorporated in 2011 and is headquartered in Tokyo, Japan. Healios K is traded on OTC Exchange in the United States.Things to note about Healios KK performance evaluation
Checking the ongoing alerts about Healios KK for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Healios KK help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Healios KK generated a negative expected return over the last 90 days | |
| Healios KK may become a speculative penny stock | |
| Healios KK has high historical volatility and very poor performance | |
| The company reported the revenue of 41 M. Net Loss for the year was (4.91 B) with profit before overhead, payroll, taxes, and interest of 41 M. | |
| Healios KK has accumulated about 12.28 B in cash with (5.09 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 237.66, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 51.0% of the company shares are held by company insiders |
- Analyzing Healios KK's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Healios KK's stock is overvalued or undervalued compared to its peers.
- Examining Healios KK's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Healios KK's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Healios KK's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Healios KK's pink sheet. These opinions can provide insight into Healios KK's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Healios Pink Sheet analysis
When running Healios KK's price analysis, check to measure Healios KK's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Healios KK is operating at the current time. Most of Healios KK's value examination focuses on studying past and present price action to predict the probability of Healios KK's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Healios KK's price. Additionally, you may evaluate how the addition of Healios KK to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |